Clinical and Translational Medicine最新文献

筛选
英文 中文
Fragment-end sequence architecture of cell-free DNA and its association with tumour DNA in non-small cell lung cancer. 非小细胞肺癌中游离DNA片段端序列结构及其与肿瘤DNA的关联。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70901
Dhruv Das, Prachi Gupta, Rahul Tambade, P A Hassan, A V S S Narayana Rao, Rajani Kant Chittela
{"title":"Fragment-end sequence architecture of cell-free DNA and its association with tumour DNA in non-small cell lung cancer.","authors":"Dhruv Das, Prachi Gupta, Rahul Tambade, P A Hassan, A V S S Narayana Rao, Rajani Kant Chittela","doi":"10.1002/ctm2.70901","DOIUrl":"10.1002/ctm2.70901","url":null,"abstract":"<p><strong>Introduction: </strong>Circulating cell-free DNA (cfDNA) fragmentation patterns provide a promising source of molecular information for liquid biopsy applications. However, the sequence features underlying fragmentation and their relationship to tumour-derived DNA remain incompletely understood. Here, we characterized fragment-end sequence signatures of extracellular cfDNA across cell lines, extracellular compartments, stress conditions and plasma from patients with non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>cfDNA derived from cell lines was characterized using Oxford Nanopore sequencing, followed by fragment-end analysis. Publicly available Nanopore cfDNA datasets from healthy individuals and NSCLC patients were analyzed to examine dinucleotide patterns and derive a motif ratio index. These signatures were further assessed for their association with estimated ctDNA abundance in an independent cohort of 50 EGFR-mutant NSCLC patients.</p><p><strong>Results: </strong>Nanopore sequencing of A549, H460 and WI38 cell-line cfDNA revealed reproducible end-motif patterns, with enrichment of AT-, GT- and CT-containing termini. Analysis of plasma cfDNA from healthy individuals showed distinct end-motif profiles from cell-line-derived cfDNA, with separation maintained after reducing 4-mer motifs to 5'-terminal dinucleotide features. An exploratory motif ratio based on these patterns showed a modest increase in lung cancer patients compared with healthy individuals. In an independent Illumina cohort of 50 NSCLC patients with activating EGFR mutations, 5'-terminal dinucleotide frequencies were associated with estimated circulating tumour DNA (ctDNA) abundance using cross-validated LASSO (Least Absolute Shrinkage and Selection Operator) regression (Spearman ρ = .73, p = 3.35 × 10<sup>‒9</sup>). The predefined motif ratio showed a strong correlation with estimated ctDNA concentration (Spearman ρ = .76, p = 1.89 × 10<sup>‒10</sup>).</p><p><strong>Conclusion: </strong>These findings suggest that simple, interpretable cfDNA end-motif signatures capture sequence features associated with ctDNA abundance and warrant further validation for non-invasive cancer monitoring.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell transcriptomic profiling reveals transcription factor-driven CD14+ monocyte programs underlying divergent wound healing outcomes in diabetic foot ulcers treated with Shangke Huangshui. 单细胞转录组学分析揭示了转录因子驱动的CD14+单核细胞程序在上可黄水治疗糖尿病足溃疡的不同伤口愈合结果中的作用。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70838
Jue Zhang, Wenyi Cao, Mingxun Luo, Zhimin Gu, Ming Mu, Junjiu Huang, Xiaotong Luo, Aisheng Wei
{"title":"Single-cell transcriptomic profiling reveals transcription factor-driven CD14<sup>+</sup> monocyte programs underlying divergent wound healing outcomes in diabetic foot ulcers treated with Shangke Huangshui.","authors":"Jue Zhang, Wenyi Cao, Mingxun Luo, Zhimin Gu, Ming Mu, Junjiu Huang, Xiaotong Luo, Aisheng Wei","doi":"10.1002/ctm2.70838","DOIUrl":"10.1002/ctm2.70838","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770200/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What one patient can teach the next. 一个病人可以教给下一个病人的东西。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70900
Ge Zhang, Mingxuan Duan, Tianshu Gu, Qian Guo, Yahui Han, Teng Li
{"title":"What one patient can teach the next.","authors":"Ge Zhang, Mingxuan Duan, Tianshu Gu, Qian Guo, Yahui Han, Teng Li","doi":"10.1002/ctm2.70900","DOIUrl":"10.1002/ctm2.70900","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer 同源重组缺陷的二分法评估不足以预测PARP抑制剂治疗卵巢癌的生物标志物
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70890
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas
{"title":"Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer","authors":"Jesenia M. Perez,&nbsp;Justin Hwang,&nbsp;Britt K. Erickson,&nbsp;Stefani N. Thomas","doi":"10.1002/ctm2.70890","DOIUrl":"https://doi.org/10.1002/ctm2.70890","url":null,"abstract":"&lt;p&gt;Predictive biomarkers of disease are essential for treatment stratification, prognosticating, and developing strategies to improve outcomes. Assessment of &lt;i&gt;BRCA1/2&lt;/i&gt; mutation status and homologous recombination deficiency (HRD) are the current approaches used to designate maintenance treatment for epithelial ovarian cancers (EOC).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; The high recurrence rate and poor 5-year survival underscores the importance of comprehensively defining one of the key characteristics of epithelial ovarian cancer: genome instability. With the development of sophisticated multi-omics techniques, the field is well-positioned to expand current dichotomous assessments of HRD to improve the utility of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) therapies in ovarian cancer.&lt;/p&gt;&lt;p&gt;The primary treatment for advanced-stage ovarian cancer is guided by disease staging from surgery, tumour histotype and primary site, &lt;i&gt;BRCA1/2&lt;/i&gt; mutation status, HRD status and patient-related factors such as functional status and comorbidities.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; After surgical cytoreduction and completion of primary platinum-based chemotherapy, patients with tumours harbouring &lt;i&gt;BRCA&lt;/i&gt; gene variants or HRD can also receive PARPi maintenance therapy (olaparib, niraparib) alone or in combination with the angiogenesis inhibitor, bevacizumab (Table 1).&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; Patients whose tumours are HRD negative (also known as Homologous Recombination Proficient (HRP)) are given bevacizumab or no further treatment in the maintenance setting.&lt;span&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/span&gt; Despite advancements in the use of neoadjuvant chemotherapy and individualised maintenance therapies with PARPi, disease recurrence is observed in 70% of patients within 3 years of first-line chemotherapy. Additionally, treatment with PARPi frequently leads to the development of haematological toxicities including anaemia, thrombocytopenia, and neutropenia; these adverse events are the main contributors to interruption and discontinuation of PARPi treatment, and they impact patients’ quality of life.&lt;span&gt;&lt;sup&gt;3&lt;/sup&gt;&lt;/span&gt; Furthermore, PARPi therapy may increase the risk of fatality due to myelodysplastic syndrome and acute myeloid leukaemia.&lt;span&gt;&lt;sup&gt;4&lt;/sup&gt;&lt;/span&gt; The likelihood of the occurrence of these and other adverse events emphasises the importance of appropriate PARPi-treatment stratification in maintenance therapy to reduce disease recurrence, prolong survival, and improve patient quality of life.&lt;/p&gt;&lt;p&gt;PARPi function by inhibiting single-strand DNA break repair by PARP1 and PARP2 enzymes, leading to the accumulation of mutations and the formation of double-strand DNA breaks.&lt;span&gt;&lt;sup&gt;5&lt;/sup&gt;&lt;/span&gt; In tumour cells with non-functional &lt;i&gt;BRCA1/2&lt;/i&gt; or HRD, double-strand DNA breaks are repaired through the error-prone non-homologous end joining (NHEJ) pathway, leading to chromosomal instability, cell cycle arrest, and ultimately cell death. This syntheti","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70890","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
In situ spatial mapping resolves macrophage-fibroblast niche reorganisation in silica-induced nodular lung fibrogenesis. 原位空间定位解决了二氧化硅诱导的结节性肺纤维化中巨噬细胞-成纤维细胞生态位重组。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70869
Lin Zhang, Jiaqi Tian, Ning Li, Qiang Li, Dandan Song, Xiaotan Shi, Shuyin Duan
{"title":"In situ spatial mapping resolves macrophage-fibroblast niche reorganisation in silica-induced nodular lung fibrogenesis.","authors":"Lin Zhang, Jiaqi Tian, Ning Li, Qiang Li, Dandan Song, Xiaotan Shi, Shuyin Duan","doi":"10.1002/ctm2.70869","DOIUrl":"10.1002/ctm2.70869","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
AARS1-mediated PHGDH lactylation promotes hepatocellular carcinoma progression by enhancing serine biosynthesis. aars1介导的PHGDH乳酸化通过增强丝氨酸生物合成促进肝细胞癌的进展。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70899
Qing Zhu, Nanyan Yang, Xiangzhuo Miao, Shiting Xu, Junming Chen, Huohui Ou, Jianmin Nie, Pengyu Zhu, Yinghao Fang, Dinghua Yang
{"title":"AARS1-mediated PHGDH lactylation promotes hepatocellular carcinoma progression by enhancing serine biosynthesis.","authors":"Qing Zhu, Nanyan Yang, Xiangzhuo Miao, Shiting Xu, Junming Chen, Huohui Ou, Jianmin Nie, Pengyu Zhu, Yinghao Fang, Dinghua Yang","doi":"10.1002/ctm2.70899","DOIUrl":"10.1002/ctm2.70899","url":null,"abstract":"<p><strong>Background: </strong>The recently described lactyltransferase activity of alanyl-tRNA synthetase 1 (AARS1) raises questions about its metabolic functions in hepatocellular carcinoma. We examined phosphoglycerate dehydrogenase (PHGDH) as a potential lactylation substrate linking AARS1 to serine metabolism and tumour growth.</p><p><strong>Methods: </strong>Public expression data and patient tissues were studied alongside proteomic, lactylomic and targeted metabolomic profiles. Cellular and xenograft experiments used gene depletion, overexpression and reconstitution with wild-type or mutant proteins. Immunoprecipitation and activity measurements assessed PHGDH regulation. Survival was examined with Kaplan‒Meier estimates and Cox regression, while experimental groups were compared by t-tests or analysis of variance.</p><p><strong>Results: </strong>Of 140 paired specimens, 119 tumours (85%) had higher AARS1 mRNA than their non-tumour counterparts. Elevated AARS1 independently predicted poorer survival, and E2F4 depletion lowered AARS1 expression. AARS1 supported malignant phenotypes, lactate production and PHGDH lactylation. Mass spectrometry detected lactylation at PHGDH-K394. Relative to wild-type PHGDH, K394R showed less lactylation and supported lower lysate enzyme activity, serine, glycine and glutathione levels. The mutant also increased reactive oxygen species, provided weaker phenotypic rescue and supported less xenograft growth. Depleting AARS1 reduced enzyme activity and malignant phenotypes in the wild-type background; no further significant reduction was detected with K394R. β-Alanine inhibited xenograft growth, but PHGDH-K394 alone could not account for its effects.</p><p><strong>Conclusions: </strong>AARS1-associated PHGDH-K394 lactylation may connect serine metabolism and redox regulation to hepatocellular carcinoma progression. Establishing therapeutic relevance will require site-specific mechanistic experiments and additional preclinical validation.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Single-cell multiomics profiling reveals tumour microenvironment landscape and sex-specific immune-suppressive feature in male breast cancer. 单细胞多组学分析揭示男性乳腺癌肿瘤微环境景观和性别特异性免疫抑制特征。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70894
Handong Sun, Ruilin Wang, Yanhao Wang, Meining Jiang, Cui-Cui Liu, Chuang Yang, Zhonglin Wang, Bing Sun, Jun Zhang, Mengtao Zhan, Zhou Fan, Yongsheng Li, Keda Yu
{"title":"Single-cell multiomics profiling reveals tumour microenvironment landscape and sex-specific immune-suppressive feature in male breast cancer.","authors":"Handong Sun, Ruilin Wang, Yanhao Wang, Meining Jiang, Cui-Cui Liu, Chuang Yang, Zhonglin Wang, Bing Sun, Jun Zhang, Mengtao Zhan, Zhou Fan, Yongsheng Li, Keda Yu","doi":"10.1002/ctm2.70894","DOIUrl":"https://doi.org/10.1002/ctm2.70894","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) represents a small proportion of all breast cancer (BC) cases, yet it is characterized by a higher rate of lymph node metastasis and poorer prognosis compared to female breast cancer (FBC). However, limited research has been conducted on MBC primarily due to its rarity and the technological constraints.</p><p><strong>Methods: </strong>To address this, we performed single-nucleus RNA sequencing (snRNA-seq) on samples from 16 MBC patients (87 518 cells) and imaging mass cytometry (IMC) on samples from 42 patients (265 137 cells), enabling a comprehensive analysis of the MBC microenvironment at both single-cell transcriptome and protein levels.</p><p><strong>Results: </strong>At the autosomal level, the MBC tumor cells and their microenvironment exhibit distinct characteristics. We found that PDZ binding kinase (PBK) expression was elevated in MBC tumor cells and linked to proliferation-related programs, whereas SRY-Box transcription factor 4 (SOX4) expression was increased in endothelial cells and associated with endothelial-mesenchymal transition (EndMT) signatures and metastatic potential. Additionally, IMC analysis revealed notable differences in the spatial features of the tumor microenvironment between MBC and FBC. Regarding sex-chromosomal regulation, the lysine demethylase 5D (KDM5D) gene originating from the Y chromosome was associated with cGAS/STING protein abundance and reduced immune cell infiltration in MBC.</p><p><strong>Conclusion: </strong>In conclusion, both autosomal and sex-chromosomal regulation may collectively contribute to the modulation of microenvironmental differences between MBC and FBC. Whether KDM5D is functionally linked to cGAS/STING signaling requires further validation. Our findings provide insights into the unique microenvironment and clinical manifestations of MBC and generate hypotheses for future functional studies.</p><p><strong>Highlights: </strong>Multi-omics profiling reveals a distinct, relatively immune-cold microenvironment in male breast cancer. PBK expression is associated with proliferation programs in MBC epithelial cells. SOX4 expression in endothelial cells is linked to an EndMT-like phenotype. KDM5D-low status is associated with reduced cGAS/STING protein levels and immune infiltration.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reducing the burden of diabetes through better care across the disease continuum. 通过在整个疾病过程中提供更好的护理来减轻糖尿病负担。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-11-01 DOI: 10.1002/ctm2.70897
Siqi Yang, Till Winfried Bärnighausen, Zhong Cao
{"title":"Reducing the burden of diabetes through better care across the disease continuum.","authors":"Siqi Yang, Till Winfried Bärnighausen, Zhong Cao","doi":"10.1002/ctm2.70897","DOIUrl":"10.1002/ctm2.70897","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Intranuclear localisation of KLF3-AS1 under the balance of histone acetylation and methylation in BMSCs ameliorates cerebral ischaemia‒reperfusion injury by preserving microglial mitochondrial function and inhibiting inflammatory polarisation 在组蛋白乙酰化和甲基化平衡的情况下,骨髓间充质干细胞中KLF3-AS1的核内定位可以通过保持小胶质细胞线粒体功能和抑制炎症极化来改善脑缺血再灌注损伤
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-10-31 DOI: 10.1002/ctm2.70870
Qian Li, Xiaowei Xie, Jie Chen, Yu Cao, Dingzhou Zhou
{"title":"Intranuclear localisation of KLF3-AS1 under the balance of histone acetylation and methylation in BMSCs ameliorates cerebral ischaemia‒reperfusion injury by preserving microglial mitochondrial function and inhibiting inflammatory polarisation","authors":"Qian Li,&nbsp;Xiaowei Xie,&nbsp;Jie Chen,&nbsp;Yu Cao,&nbsp;Dingzhou Zhou","doi":"10.1002/ctm2.70870","DOIUrl":"https://doi.org/10.1002/ctm2.70870","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Ischaemic stroke occurs when blood flow to the brain is obstructed. Rapid restoration of blood supply frequently induces cerebral ischaemia‒reperfusion injury (CIRI). Bone marrow mesenchymal stem cell (BMSC)-derived exosomes exhibit promising therapeutic potential for CIRI. In-depth exploration of their therapeutic mechanisms holds crucial significance for CIRI management.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The middle cerebral artery occlusion/reperfusion (MCAO) model was established in mice. An in vitro ischaemic stroke model was established by treating BV-2 cells with oxygen‒glucose deprivation/reoxygenation (OGD/R). Exosomes were isolated from BMSCs and intranasally administrated into mice or added into BV-2 cells. Neurological deficits, grasping and coordination function were evaluated. Cell viability, apoptosis, proliferation and migration were examined. The localisation of KLF3-AS1 was examined by combined staining of immunofluorescence and fluorescence in situ hybridisation. Intracellular Ca&lt;sup&gt;2+&lt;/sup&gt; and adenosine triphosphate levels, mitochondrial reactive oxygen species and membrane potential were assessed.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;KLF3-AS1 enhanced BMSC viability, proliferation and migration, accompanied by epigenetic reprogramming at its promoter characterised by increased H3K27 acetylation (H3K27Ac) and decreased H3K27 trimethylation (H3K27Me3). BMSC-derived KLF3-AS1-enriched exosomes indicated therapeutic efficacy in both in vivo and in vitro models of cerebral ischaemia. In MCAO-induced mice, these exosomes alleviated neurological deficits and shifted microglial polarisation from pro-inflammatory M1-like to anti-inflammatory M2-like phenotypes. Similar effects were observed in OGD/R-treated BV-2 microglia, where KLF3-AS1-enriched exosomes attenuated oxidative stress and mitochondrial dysfunction while upregulating Silent Information Regulator 3 (SIRT3) expression. Mechanistically, KLF3-AS1 facilitated ETS Variant Transcription Factor 4 (ETV4) nuclear translocation to activate SIRT3 transcription in microglia, and inhibition of SIRT3 abolished the neuroprotective effects of exosomal KLF3-AS1.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;BMSC-derived exosomes delivering KLF3-AS1 ameliorates CIRI by preserving microglial mitochondrial function and inhibiting inflammatory polarisation, highlighting KLF3-AS1 as a critical epigenetic regulator and exosome-mediated therapeutic agent for CIRI through the ETV4/SIRT3 axis.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70870","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149312794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling 表观遗传沉默PDLIM4通过损害BTF3自噬降解和激活PI3K/Akt信号传导促进结直肠癌。
IF 7.9 1区 医学
Clinical and Translational Medicine Pub Date : 2026-10-30 DOI: 10.1002/ctm2.70882
Jiaxing Wang, Chuan-Guo Guo, Lingyu Qi, Songyuan Hou, Boshen Lin, Tong Ye, Ye Zong, Shutian Zhang, Nan Zhang, Peng Li, Si Liu
{"title":"Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling","authors":"Jiaxing Wang,&nbsp;Chuan-Guo Guo,&nbsp;Lingyu Qi,&nbsp;Songyuan Hou,&nbsp;Boshen Lin,&nbsp;Tong Ye,&nbsp;Ye Zong,&nbsp;Shutian Zhang,&nbsp;Nan Zhang,&nbsp;Peng Li,&nbsp;Si Liu","doi":"10.1002/ctm2.70882","DOIUrl":"10.1002/ctm2.70882","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Epigenetic silencing of tumour suppressor genes is a pivotal early event in colorectal cancer (CRC) pathogenesis. PDZ and LIM Domain 4 (PDLIM4) is a member of the PDZ-LIM family with context-dependent roles in tumour progression across different malignancies. However, its specific role and epigenetic regulation in colorectal cancer (CRC) remain elusive.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We integrated multi-omics datasets and clinical cohorts to evaluate PDLIM4 expression and promoter methylation. Stool DNA was analyzed to assess the feasibility of non-invasive detection of PDLIM4 promoter methylation. PDLIM4 knockout and overexpression cell lines were constructed to perform functional assays including proliferation, apoptosis, and stemness. In vivo experiments were validated utilizing xenograft mice or an azoxymethane (AOM)/ dextran sulphate sodium salt (DSS) CRC mouse model with intestinal epithelial cell-specific overexpression of PDLIM4. Mechanistic investigations were conducted using coimmunoprecipitation coupled with mass spectrometry, RNA sequencing, ChIP-qPCR and pharmacological rescue experiments.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;We identified a progressive loss of PDLIM4 protein along the normal-adenoma-carcinoma sequence, driven by DNMT3A-mediated promoter hypermethylation, and lower PDLIM4 expression was associated with adverse patient prognosis. PDLIM4 methylation was also significantly increased in stool DNA from CRC patients compared with healthy controls. Mechanistically, genetic ablation of PDLIM4 significantly blunted the therapeutic efficacy of the DNA demethylating agent 5-Azacytidine against CRC. Functionally, PDLIM4 restoration suppressed CRC cell proliferation and stemness while enhancing apoptosis in vitro, and reduced tumour growth in both AOM/DSS and xenograft models in vivo. At the molecular level, PDLIM4 interacted with BTF3 and promoted its autophagic-lysosomal degradation, thereby limiting PI3K/Akt signalling, with NTRK2 identified as a potential transcriptional target linking BTF3 to PI3K/Akt activation.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Conclusion&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;DNMT3A-mediated silencing of PDLIM4 is an early epigenetic event that facilitates CRC progression. PDLIM4 suppresses tumour growth by promoting BTF3 degradation, thereby restricting PI3K/Akt signalling. Thus, PDLIM4 methylation may have potential as a biomarker for early CRC detection.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Key points&lt;/h3&gt;\u0000 ","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70882","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书